{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:19:18Z","timestamp":1785885558415,"version":"3.56.0"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bcp.2024.116667","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:32:09Z","timestamp":1733531529000},"page":"116667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The NLRP3 inflammasome: A central player in multiple sclerosis"],"prefix":"10.1016","volume":"232","author":[{"given":"Almudena","family":"Ot\u00e1lora-Alcaraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Or\u00f3-Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody Cui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Costelloe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pabitra H.","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-2291","authenticated-orcid":false,"given":"Eric J.","family":"Downer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116667_b0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12974-020-01944-9","article-title":"Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets","volume":"17","author":"Govindarajan","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116667_b0010","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458520932776","article-title":"The role of inflammasomes in multiple sclerosis","volume":"27","author":"Yavarpour-Bali","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.bcp.2024.116667_b0015","unstructured":"Multiple Sclerosis: Facts, Statistics, and You, Healthline (2022). https:\/\/www.healthline.com\/health\/multiple-sclerosis\/facts-statistics-infographic (accessed September 30, 2022)."},{"key":"10.1016\/j.bcp.2024.116667_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.msard.2017.02.010","article-title":"Incidence of multiple sclerosis in the Republic of Ireland: a prospective population-based study","volume":"13","author":"O\u2019Connell","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b0025","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.3390\/ijms21124223","article-title":"Focus on the Role of NLRP3 Inflammasome in Diseases","volume":"21","author":"Fusco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbi.2020.11.004","article-title":"Therapeutic role of inflammasome inhibitors in neurodegenerative disorders","volume":"91","author":"Lahooti","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2024.116667_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107880","article-title":"Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis","volume":"227","author":"Shao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116667_b0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis*, defining the clinical course of multiple sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2024.116667_b0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2024.116667_b0050","author":"Barclay","year":"2016","journal-title":"Inflammasome Activation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis (EAE)"},{"key":"10.1016\/j.bcp.2024.116667_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jnc.13217","article-title":"The pathogenic role of the inflammasome in neurodegenerative diseases","volume":"136","author":"Freeman","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2024.116667_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Time for a new mechanism-driven framework to define multiple sclerosis progression","volume":"22","author":"Kuhlmann","year":"2022","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.bcp.2024.116667_b0065","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS,","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b0070","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2024.116667_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab134","article-title":"Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression","volume":"3","author":"Treaba","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0080","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awaa275","article-title":"Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis","volume":"143","author":"Sucksdorff","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2024.116667_b0085","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bcp.2024.116667_b0090","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/cells11121959","article-title":"Ocrelizumab in patients with active primary progressive multiple sclerosis: clinical outcomes and immune markers of treatment response","volume":"11","author":"Boziki","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116667_b0095","doi-asserted-by":"crossref","unstructured":"A. Gajofatto, M.D. Benedetti, Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?, World J. Clin. Cases\u00a0: WJCC 3 (2015) 545. 10.12998\/wjcc.v3.i7.545.","DOI":"10.12998\/wjcc.v3.i7.545"},{"key":"10.1016\/j.bcp.2024.116667_b0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3906\/biy-1909-31","article-title":"The NLRP3 inflammasome: a new player in neurological diseases","volume":"43","author":"Eren","year":"2019","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/emm.2006.40","article-title":"Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson\u2019s disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2024.116667_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212676","article-title":"Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection","volume":"14","author":"Hedstr\u00f6m","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116667_b0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s11658-024-00575-9","article-title":"Mitochondrial (mt)DNA\u2013cyclic GMP\u2013AMP synthase (cGAS)\u2013stimulator of interferon genes (STING) signaling promotes pyroptosis of macrophages via interferon regulatory factor (IRF)7\/IRF3 activation to aggravate lung injury during severe acute pancreatitis","volume":"29","author":"Peng","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bcp.2024.116667_b0125","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1016\/j.cell.2024.05.031","article-title":"STING orchestrates the neuronal inflammatory stress response in multiple sclerosis","volume":"187","author":"Woo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116667_b0130","first-page":"1","article-title":"The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases","author":"Wang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2024.116667_b0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2013.11.002","article-title":"The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells","volume":"39","author":"Lahaye","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116667_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13046-021-01850-9","article-title":"Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis","volume":"40","author":"Hu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116667_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.905109","article-title":"Dysregulation of the cGAS-STING pathway in monogenic autoinflammation and lupus","volume":"13","author":"Wobma","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0150","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bcp.2024.116667_b0160","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006049","article-title":"Signaling in innate immunity and inflammation","volume":"4","author":"Newton","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.894298","article-title":"Focus on the role of the NLRP3 inflammasome in multiple sclerosis: pathogenesis, diagnosis, and therapeutics","volume":"15","author":"Cui","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/icb.2014.5","article-title":"Caspases and inflammasomes in metabolic inflammation","volume":"92","author":"Skeldon","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0175","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116667_b0180","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0185","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1126\/science.291.5508.1544","article-title":"Induction of direct antimicrobial activity through mammalian toll-like receptors","volume":"291","author":"Thoma-Uszynski","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116667_b0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.bcp.2024.116667_b0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12296","article-title":"Regulation of inflammasome activation","volume":"265","author":"Man","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2024.116667_b0200","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/brain\/awaa084","article-title":"NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients","volume":"143","author":"Malhotra","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2024.116667_b0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116667_b0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcp.2016.05.002","article-title":"Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation","volume":"112","author":"Liu","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.intimp.2015.06.011","article-title":"Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells","volume":"28","author":"Miglio","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0220","doi-asserted-by":"crossref","unstructured":"B. Tastan, B.I. Arioz, K.U. Tufekci, E. Tarakcioglu, C.P. Gonul, K. Genc, S. Genc, Dimethyl Fumarate Alleviates NLRP3 Inflammasome Activation in Microglia and Sickness Behavior in LPS-Challenged Mice, Front. Immunol. 12 (2021). https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.737065 (accessed January 12, 2023).","DOI":"10.3389\/fimmu.2021.737065"},{"key":"10.1016\/j.bcp.2024.116667_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118582","article-title":"Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation","volume":"263","author":"Guo","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0230","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2024.116667_b0235","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0240","first-page":"17","article-title":"The role of bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"CritRevImmunol"},{"key":"10.1016\/j.bcp.2024.116667_b0245","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201656","article-title":"BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity","volume":"218","author":"Bittner","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116667_b0250","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis: from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet."},{"key":"10.1016\/j.bcp.2024.116667_b0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.msard.2019.01.023","article-title":"Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis","volume":"29","author":"Soares","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b0260","doi-asserted-by":"crossref","unstructured":"P.L. De Jager, X. Jia, J. Wang, P.I.W. de Bakker, L. Ottoboni, N.T. Aggarwal, L. Piccio, S. Raychaudhuri, D. Tran, C. Aubin, R. Briskin, S. Romano, International MS Genetics Consortium, S.E. Baranzini, J.L. McCauley, M.A. Pericak-Vance, J.L. Haines, R.A. Gibson, Y. Naeglin, B. Uitdehaag, P.M. Matthews, L. Kappos, C. Polman, W.L. McArdle, D.P. Strachan, D. Evans, A.H. Cross, M.J. Daly, A. Compston, S.J. Sawcer, H.L. Weiner, S.L. Hauser, D.A. Hafler, J.R. Oksenberg, Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci, Nat. Genet. 41 (2009) 776\u2013782. 10.1038\/ng.401.","DOI":"10.1038\/ng.401"},{"key":"10.1016\/j.bcp.2024.116667_b0265","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/iji.12388","article-title":"TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak population","volume":"45","author":"Javor","year":"2018","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.bcp.2024.116667_b0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12974-020-01867-5","article-title":"Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants","volume":"17","author":"Mulazzani","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116667_b0275","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.bcp.2024.116667_b0280","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1212\/NXI.0000000000000109","article-title":"Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations","volume":"2","author":"Schuh","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.bcp.2024.116667_b0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11882-010-0160-9","article-title":"Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response","volume":"11","author":"Yu","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.bcp.2024.116667_b0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/iji.12401","article-title":"Association of nod-like receptor protein-3 single nucleotide gene polymorphisms and expression with the susceptibility to relapsing-remitting multiple sclerosis","volume":"45","author":"Imani","year":"2018","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.bcp.2024.116667_b0295","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/brain\/awu388","article-title":"NLRP3 inflammasome is associated with the response to IFN-\u03b2 in patients with multiple sclerosis","volume":"138","author":"Malhotra","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2024.116667_b0300","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11033-013-3013-5","article-title":"Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis","volume":"41","author":"Karakas Celik","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2024.116667_b0305","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clineuro.2016.04.027","article-title":"The association of IL-18 gene promoter polymorphisms and the levels of serum IL-18 on the risk of multiple sclerosis","volume":"146","author":"Orhan","year":"2016","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.bcp.2024.116667_b0310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00011-012-0556-1","article-title":"Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis","volume":"62","author":"Huang","year":"2013","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bcp.2024.116667_b0315","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3109\/00207454.2013.795563","article-title":"Multiple sclerosis: association with the interleukin-1 gene family polymorphisms in the Turkish population","volume":"123","author":"Isik","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0320","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1038\/s41598-019-45598-x","article-title":"Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic variants in the inflammasome regulatory genes","volume":"9","author":"Vidmar","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116667_b0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fneur.2018.00135","article-title":"Inflammasome proteins as biomarkers of multiple sclerosis","author":"Keane","year":"2018","journal-title":"Front Neurol 9"},{"key":"10.1016\/j.bcp.2024.116667_b0330","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms23115877","article-title":"Current and Future Biomarkers in Multiple Sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bcp.2024.116667_b0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-0404.2001.00356.x","article-title":"IL-18 in patients with multiple sclerosis","volume":"104","author":"Losy","year":"2001","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bcp.2024.116667_b0340","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2011.12.008","article-title":"Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis","volume":"243","author":"Chen","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0345","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1191\/1352458504ms1071oa","article-title":"Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis","volume":"10","author":"Huang","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.bcp.2024.116667_b0350","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2014.02.014","article-title":"Cerebrospinal fluid IL-1\u03b2 correlates with cortical pathology load in multiple sclerosis at clinical onset","volume":"270","author":"Seppi","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0355","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molimm.2014.10.008","article-title":"Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis","volume":"63","author":"Peelen","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2015.02.006","article-title":"Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis","volume":"280","author":"Hagman","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.11.004","article-title":"The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy","volume":"207","author":"Dujmovic","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/ceji.2020.96877","article-title":"Serum levels of inflammasome pathway factors in clinically isolated syndrome and multiple sclerosis patients: a pilot study","volume":"45","author":"Tamam","year":"2020","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0375","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41467-018-04376-5","article-title":"A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation","volume":"9","author":"Voet","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0380","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.3168","article-title":"Animal models of multiple sclerosis: the good, the bad and the bottom line","volume":"15","author":"Ransohoff","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0385","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2024.116667_b0390","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0395","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/859145","article-title":"NLRP3 inflammasome and MS\/EAE","volume":"2013","author":"Inoue","year":"2013","journal-title":"Autoimmune Diseases"},{"key":"10.1016\/j.bcp.2024.116667_b0400","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4049\/jimmunol.0904145","article-title":"NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses","volume":"185","author":"Gris","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0405","doi-asserted-by":"crossref","first-page":"15811","DOI":"10.1523\/JNEUROSCI.4088-10.2010","article-title":"The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18","volume":"30","author":"Jha","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0410","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.4049\/jimmunol.1000217","article-title":"Cutting edge: critical role for PYCARD\/ASC in the development of experimental autoimmune encephalomyelitis","volume":"184","author":"Shaw","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0415","first-page":"ra38","article-title":"Interferon-\u03b2 therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome","author":"Inoue","year":"2012","journal-title":"Sci Signal 5"},{"key":"10.1016\/j.bcp.2024.116667_b0420","series-title":"Proceedings of the National Academy of Sciences","first-page":"10480","article-title":"NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis","author":"Inoue","year":"2012"},{"key":"10.1016\/j.bcp.2024.116667_b0425","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ni.3389","article-title":"T cell-intrinsic ASC critically promotes TH17-mediated experimental autoimmune encephalomyelitis","volume":"17","author":"Martin","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0430","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.165.6.3099","article-title":"IL-18 directs autoreactive T Cells and promotes autodestruction in the central nervous system via induction of IFN-\u03b3 by NK cells1","volume":"165","author":"Shi","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0435","series-title":"Proceedings of the National Academy of Sciences","first-page":"E6065","article-title":"Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis","author":"McKenzie","year":"2018"},{"key":"10.1016\/j.bcp.2024.116667_b0440","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0002-9440(10)64436-7","article-title":"A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration","volume":"161","author":"Ahmed","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2024.116667_b0445","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor ameliorates experimental autoimmune encephalomyelitis pathogenesis","volume":"10","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2565-2","article-title":"Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype","volume":"11","author":"Hou","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2024.116667_b0455","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/jnc.15650","article-title":"Investigating the NLRP3 inflammasome and its regulator miR-223-3p in multiple sclerosis and experimental demyelination","volume":"163","author":"Galloway","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2024.116667_b0460","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12974-020-01826-0","article-title":"IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis","volume":"17","author":"Desu","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116667_b0465","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","article-title":"Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome","volume":"30","author":"Ammar","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bcp.2024.116667_b0470","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bbrc.2018.07.143","article-title":"Tetramethylpyrazine ameliorates experimental autoimmune encephalomyelitis by modulating the inflammatory response","volume":"503","author":"Bai","year":"2018","journal-title":"Biochem.Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0475","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12031-020-01637-1","article-title":"Sinomenine alleviates murine experimental autoimmune encephalomyelitis model of multiple sclerosis through inhibiting NLRP3 inflammasome","volume":"71","author":"Kiasalari","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0480","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/cns.12758","article-title":"Activating \u03b17 nicotinic acetylcholine receptor inhibits NLRP3 inflammasome through regulation of \u03b2-arrestin-1","volume":"23","author":"Ke","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2024.116667_b0485","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2024.116667_b0490","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0495","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ijms22020872","article-title":"Structure, activation and regulation of NLRP3 and AIM2 inflammasomes","volume":"22","author":"Sharma","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0500","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/ijms25031372","article-title":"Response to fingolimod in multiple sclerosis patients is associated with a differential transcriptomic regulation","volume":"25","author":"S\u00e1nchez-Sanz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0505","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0510","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0515","series-title":"Proceedings of the National Academy of Sciences","article-title":"Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation","author":"Ohto","year":"2022"},{"key":"10.1016\/j.bcp.2024.116667_b0520","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1021\/acs.jmedchem.4c00504","article-title":"Hit-to-lead optimization of the natural product oridonin as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activity","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116667_b0525","article-title":"Inhibition of the NLRP3 inflammasome activation by manoalide ameliorates experimental autoimmune encephalomyelitis pathogenesis","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0530","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0535","article-title":"An RRx-001 analogue with potent anti-NLRP3 inflammasome activity but without high-energy nitro functional groups","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102515","article-title":"Recent advances in the NEK7-licensed NLRP3 inflammasome activation: mechanisms, role in diseases and related inhibitors","volume":"113","author":"Zhao","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2024.116667_b0545","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4049\/jimmunol.1700245","article-title":"NLRP3 and potassium efflux drive rapid IL-1\u03b2 release from primary human monocytes during toxoplasma gondii infection","volume":"199","author":"Gov","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0555","doi-asserted-by":"crossref","first-page":"E9371","DOI":"10.1073\/pnas.1812744115","article-title":"Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming","volume":"115","author":"Green","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116667_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127186","article-title":"Synthesis and evaluation of NLRP3-inhibitory sulfonylurea [11C]MCC950 in healthy animals","volume":"30","author":"Hill","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116667_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111442","article-title":"Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease","volume":"138","author":"Chen","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116667_b0570","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116667_b0575","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12035-023-03618-y","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 alleviates neurological impairment in the brain of EAE mice","volume":"61","author":"Hou","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2024.116667_b0580","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116667_b0585","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-017-0953-z","article-title":"Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis","volume":"14","author":"Gerzanich","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116667_b0590","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116667_b0595","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1208\/s12248-013-9514-2","article-title":"Effects of selected OATP and\/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide","volume":"15","author":"Tournier","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.bcp.2024.116667_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113994","article-title":"[11C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body","volume":"156","author":"Marie","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116667_b0605","doi-asserted-by":"crossref","first-page":"e1455","DOI":"10.1002\/cti2.1455","article-title":"A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases","volume":"12","author":"Docherty","year":"2023","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0610","doi-asserted-by":"crossref","unstructured":"C. Marchetti, B. Swartzwelter, F. Gamboni, C.P. Neff, K. Richter, T. Azam, S. Carta, I. Tengesdal, T. Nemkov, A. D\u2019Alessandro, C. Henry, G.S. Jones, S.A. Goodrich, J.P. St. Laurent, T.M. Jones, C.L. Scribner, R.B. Barrow, R.D. Altman, D.B. Skouras, M. Gattorno, V. Grau, S. Janciauskiene, A. Rubartelli, L.A.B. Joosten, C.A. Dinarello, OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proceedings of the National Academy of Sciences 115 (2018) E1530\u2013E1539. doi:10.1073\/pnas.1716095115.","DOI":"10.1073\/pnas.1716095115"},{"key":"10.1016\/j.bcp.2024.116667_b0615","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12974-023-02830-w","article-title":"Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease","volume":"20","author":"Amo-Aparicio","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116667_b0620","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bcp.2024.116667_b0625","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0630","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.intimp.2009.01.002","article-title":"Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia","volume":"9","author":"Xu","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0635","first-page":"261","article-title":"A comparison of the signal pathways between the TNF alpha-and oridonin-induced murine L929 fibrosarcoma cell death","volume":"59","author":"Huang","year":"2005","journal-title":"Acta Med. Okayama"},{"key":"10.1016\/j.bcp.2024.116667_b0640","doi-asserted-by":"crossref","first-page":"68153","DOI":"10.18632\/oncotarget.19249","article-title":"Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264. 7 cells and acute lung injury","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116667_b0645","first-page":"492","article-title":"Oridonin ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-\u03baB signaling in T lymphocytes","volume":"36","author":"Yang","year":"2020","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.bcp.2024.116667_b0650","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.gendis.2020.06.010","article-title":"Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance","volume":"8","author":"Liu","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.bcp.2024.116667_b0655","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/md202073","article-title":"Drugs and Cosmetics from the Sea","volume":"2","author":"Kijjoa","year":"2004","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bcp.2024.116667_b0660","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1204143","article-title":"RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist","volume":"13","author":"Oronsky","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116667_b0665","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1074\/jbc.M117.797126","article-title":"The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1\u03b2 transcription and activate the NLRP3 inflammasome","volume":"292","author":"Domingo-Fern\u00e1ndez","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116667_b0670","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116667_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00391","article-title":"Nuclear Factor \u03baB (NF-\u03baB)\u2013mediated inflammation in multiple sclerosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0680","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40199-015-0131-8","article-title":"A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis","volume":"23","author":"Giacoppo","year":"2015","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116667_b0685","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2019.06.033","article-title":"Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis","volume":"516","author":"Zhou","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105923","article-title":"Combination of Imipramine, a sphingomyelinase inhibitor, and \u03b2-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE)","volume":"77","author":"Askari","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0695","doi-asserted-by":"crossref","first-page":"13968","DOI":"10.4238\/2015.October.29.17","article-title":"NLRP3 rs35829419 polymorphism is associated with increased susceptibility to multiple diseases in humans","volume":"14","author":"Zhang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.bcp.2024.116667_b0700","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2492\/inflammregen.30.542","article-title":"Fingolimod (FTY720) ameliorates experimental autoimmune encephalomyelitis (EAE) II. FTY720 decreases infiltration of Th17 and Th1 cells into the central nervous system in EAE","volume":"30","author":"Seki","year":"2010","journal-title":"Inflamm. Regener."},{"key":"10.1016\/j.bcp.2024.116667_b0705","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide","volume":"76","author":"Colombo","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2024.116667_b0710","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000001106","article-title":"Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn","volume":"159","author":"Doolen","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2024.116667_b0715","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2018.02.016","article-title":"Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis","volume":"318","author":"Smith","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0720","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.921916","article-title":"Gliosis attenuation in experimental autoimmune encephalomyelitis by a combination of dimethyl fumarate and pregabalin","volume":"16","author":"Hoelz","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577163","article-title":"Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms","author":"das Neves","year":"2020","journal-title":"Journal of Neuroimmunology 340"},{"key":"10.1016\/j.bcp.2024.116667_b0730","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","article-title":"Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration","volume":"145","author":"Schilling","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0735","doi-asserted-by":"crossref","unstructured":"B.F. Pinto, L.N.B. Ribeiro, G.B.R.F. da Silva, C.S. Freitas, L. Kraemer, F.M.S. Oliveira, M.C. Cl\u00edmaco, F.A.G. Mour\u00e3o, G.S.P. dos Santos, S.R. B\u00e9la, I.L. da S. Gurgel, F. de L. Leite, A.G. de Oliveira, M.R.S. da P. Vilela, O.C. Oliveira-Lima, F.M. Soriani, R.T. Fujiwara, A. Birbrair, R.C. Russo, J. Carvalho-Tavares, Inhalation of dimethyl fumarate-encapsulated solid lipid nanoparticles attenuate clinical signs of experimental autoimmune encephalomyelitis and pulmonary inflammatory dysfunction in mice, Clin. Sci. 136 (2022) 81\u2013101. 10.1042\/CS20210792.","DOI":"10.1042\/CS20210792"},{"key":"10.1016\/j.bcp.2024.116667_b0740","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1391949","article-title":"Dimethyl fumarate modulates the regulatory T cell response in the mesenteric lymph nodes of mice with experimental autoimmune encephalomyelitis","volume":"15","author":"Lima","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0745","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02132","article-title":"Induction of regulatory properties in the intestinal immune system by dimethyl fumarate in lewis rat experimental autoimmune neuritis","volume":"10","author":"Pitarokoili","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0750","doi-asserted-by":"crossref","DOI":"10.1042\/NS20200080","article-title":"Cannabidiol modulation of oxidative stress and signalling","volume":"5","author":"Pereira","year":"2021","journal-title":"Neuronal Signaling"},{"key":"10.1016\/j.bcp.2024.116667_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116082","article-title":"Toll-like receptor signalling as a cannabinoid target","volume":"222","author":"Cui Sun","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0760","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/molecules27061763","article-title":"Botanically-derived \u03949-tetrahydrocannabinol and cannabidiol, and their 1:1 combination, modulate toll-like receptor 3 and 4 signalling in immune cells from people with multiple sclerosis","volume":"27","author":"Fitzpatrick","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2024.116667_b0765","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.neuropharm.2016.04.009","article-title":"Toll-like receptor signalling as a cannabinoid target in multiple Sclerosis","volume":"113","author":"Fitzpatrick","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2024.116667_b0770","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000357427","article-title":"Nabiximols (THC\/CBD oromucosal spray, sativex\u00ae) in clinical practice - results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity","volume":"71","author":"Flachenecker","year":"2014","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bcp.2024.116667_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01782","article-title":"Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells","volume":"9","author":"Elliott","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0780","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11481-021-10023-6","article-title":"Effects of orally administered cannabidiol on neuroinflammation and intestinal inflammation in the attenuation of experimental autoimmune encephalomyelitis","volume":"17","author":"Dopkins","year":"2022","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0785","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2017.08.017","article-title":"Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis","volume":"298","author":"Gonz\u00e1lez-Garc\u00eda","year":"2017","journal-title":"Experim. Neurol."},{"key":"10.1016\/j.bcp.2024.116667_b0790","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbi.2019.07.028","article-title":"Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome","volume":"82","author":"Al-Ghezi","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2024.116667_b0795","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.msard.2015.08.001","article-title":"The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to \u03949-tetrahydrocannabinol acting through CB1 receptors","volume":"4","author":"Moreno-Martet","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b0800","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0165-5728(89)90075-1","article-title":"\u03949-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis","volume":"23","author":"Lyman","year":"1989","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0805","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0162-3109(94)90056-6","article-title":"Suppression of experimetal autoimmune encephalomyelitis by cannabinoids","volume":"28","author":"Wirguin","year":"1994","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.bcp.2024.116667_b0810","doi-asserted-by":"crossref","unstructured":"F. da S. Rodrigues, W.R. Newton, I.D. Tassinari, F.H. da Cunha Xavier, A. Marx, L.S. de Fraga, K. Wright, R.P. Guedes, V. Bambini-Jr, Cannabidiol prevents LPS-induced inflammation by inhibiting the NLRP3 inflammasome and iNOS activity in BV2 microglia cells via CB2 receptors and PPAR\u03b3, Neurochem. Int. 177 (2024) 105769. 10.1016\/j.neuint.2024.105769.","DOI":"10.1016\/j.neuint.2024.105769"},{"key":"10.1016\/j.bcp.2024.116667_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577217","article-title":"MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by \u03949-tetrahydrocannabinol and cannabidiol in human macrophages","volume":"343","author":"Fitzpatrick","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2024.116667_b0820","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/acs.jnatprod.0c00138","article-title":"Inhibitory effect of cannabidiol on the activation of NLRP3 inflammasome is associated with its modulation of the P2X7 receptor in human monocytes","volume":"83","author":"Liu","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bcp.2024.116667_b0825","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/cells11091391","article-title":"Cannabinoids alleviate the LPS-induced cytokine storm via attenuating NLRP3 inflammasome signaling and TYK2-mediated STAT3 signaling pathways In Vitro","volume":"11","author":"Suryavanshi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116667_b0830","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acschemneuro.0c00075","article-title":"Anti-inflammatory potential of terpenes present in cannabis sativa L","volume":"11","author":"Downer","year":"2020","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bcp.2024.116667_b0835","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopha.2017.04.092","article-title":"\u03b2-caryophyllene ameliorates the development of experimental autoimmune encephalomyelitis in C57BL\/6 mice","volume":"91","author":"Fontes","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116667_b0840","doi-asserted-by":"crossref","unstructured":"W.-Y. Li, F. Yang, J.-H. Chen, G.-F. Ren, \u03b2-Caryophyllene Ameliorates MSU-Induced Gouty Arthritis and inflammation through inhibiting NLRP3 and NF-\u03baB signal pathway: In Silico and In Vivo, Frontiers in Pharmacology 12 (2021). 10.3389\/fphar.2021.651305.","DOI":"10.3389\/fphar.2021.651305"},{"key":"10.1016\/j.bcp.2024.116667_b0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109602","article-title":"Disease-modifying effects of cannabidiol, \u03b2-caryophyllene and their combination in Syn1-Cre\/Scn1aWT\/A1783V mice, a preclinical model of dravet syndrome","volume":"237","author":"Alonso","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2024.116667_b0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-022-00168-3","article-title":"Chemical constituents of industrial hemp roots and their anti-inflammatory activities","volume":"5","author":"Huang","year":"2023","journal-title":"J Cannabis Res"},{"key":"10.1016\/j.bcp.2024.116667_b0855","first-page":"1","article-title":"Mechanisms of action and pharmacokinetics of cannabis","volume":"25","author":"Chayasirisobhon","year":"2020","journal-title":"Perm. J."},{"key":"10.1016\/j.bcp.2024.116667_b0860","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.1203546","article-title":"Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-\u03baB signaling","volume":"191","author":"Yin","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0865","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.intimp.2009.01.025","article-title":"Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production","volume":"9","author":"Xie","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0870","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-015-9617-x","article-title":"Apigenin, a natural flavonoid, attenuates EAE severity through the modulation of dendritic cell and other immune cell functions","volume":"11","author":"Ginwala","year":"2016","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2021.100139","article-title":"Inhibition of c-JNK\/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: evidence from CSF, blood plasma and brain samples","volume":"1","author":"Singh","year":"2021","journal-title":"Phytomed. Plus"},{"key":"10.1016\/j.bcp.2024.116667_b0880","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cbf.3841","article-title":"Curcumin and targeting of molecular and metabolic pathways in multiple sclerosis","volume":"41","author":"Yazdani","year":"2023","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.bcp.2024.116667_b0885","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.4049\/jimmunol.179.10.7121","article-title":"Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation","volume":"179","author":"Nicholas","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b0890","doi-asserted-by":"crossref","unstructured":"M.H. Harirchian, E. Karimi, S. Bitarafan, Diet and disease-related outcomes in multiple sclerosis: a systematic review of clinical trials, Curr. J. Neurol. 21 (2022) 52\u201363. 10.18502\/cjn.v21i1.9362.","DOI":"10.18502\/cjn.v21i1.9362"},{"key":"10.1016\/j.bcp.2024.116667_b0895","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40120-023-00505-5","article-title":"Dietary patterns and their associations with symptom levels among people with multiple sclerosis: a real-world digital study","volume":"12","author":"Skovgaard","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.bcp.2024.116667_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105636","article-title":"Associations between diet and disease progression and symptomatology in multiple sclerosis: a systematic review of observational studies","volume":"87","author":"Solsona","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b0905","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1089\/ars.2020.8257","article-title":"Loop between NLRP3 inflammasome and reactive oxygen species","volume":"36","author":"Dominic","year":"2022","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2024.116667_b0910","series-title":"Advances in Protein Chemistry and Structural Biology","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/bs.apcsb.2019.08.007","article-title":"Chapter Seven - Microglial NLRP3 inflammasome activation in multiple sclerosis","author":"Olcum","year":"2020"},{"key":"10.1016\/j.bcp.2024.116667_b0915","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00011-013-0667-3","article-title":"OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation","volume":"63","author":"Liu","year":"2014","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bcp.2024.116667_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106998","article-title":"Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: effect on reactive oxygen species\/NLRP3 pathway","volume":"88","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0925","article-title":"The influence of reactive oxygen species in the immune system and pathogenesis of multiple sclerosis","volume":"2020","author":"Javad Tavassolifar","year":"2020","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.bcp.2024.116667_b0930","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116667_b0935","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Naing","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116667_b0940","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbrc.2021.08.010","article-title":"AZD8055 ameliorates experimental autoimmune encephalomyelitis via the mTOR\/ROS\/NLRP3 pathway","volume":"573","author":"He","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0945","doi-asserted-by":"crossref","first-page":"12454","DOI":"10.1074\/jbc.M109.093252","article-title":"Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis*","volume":"285","author":"Ippagunta","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116667_b0950","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12964-020-00572-3","article-title":"Ethanol-activated CaMKII signaling induces neuronal apoptosis through Drp1-mediated excessive mitochondrial fission and JNK1-dependent NLRP3 inflammasome activation","volume":"18","author":"Lim","year":"2020","journal-title":"Cell Commun. Signaling"},{"key":"10.1016\/j.bcp.2024.116667_b0955","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.abb.2019.02.020","article-title":"Effects of phosphorylation on the NLRP3 inflammasome","volume":"670","author":"Sandall","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2024.116667_b0960","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2017.08.017","article-title":"NLRP3 phosphorylation is an essential priming event for inflammasome activation","volume":"68","author":"Song","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2024.116667_b0965","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.intimp.2017.01.032","article-title":"Sinigrin inhibits production of inflammatory mediators by suppressing NF-\u03baB\/MAPK pathways or NLRP3 inflammasome activation in macrophages","volume":"45","author":"Lee","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116667_b0970","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cells9102154","article-title":"c-Jun N-terminal kinase as a therapeutic target in experimental autoimmune encephalomyelitis","volume":"9","author":"Bagnoud","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116667_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149978","article-title":"The protease caspase-1: activation pathways and functions","volume":"717","author":"Zhen","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2024.116667_b0980","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cmdc.200900531","article-title":"A Highly potent and selective caspase 1 inhibitor that utilizes a Key 3-cyanopropanoic acid Moiety","volume":"5","author":"Boxer","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2024.116667_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115861","article-title":"Interleukin-1\u03b2 converting enzyme (ICE): A comprehensive review on discovery and development of caspase-1 inhibitors","volume":"261","author":"Modi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116667_b0990","first-page":"568","article-title":"The potential for caspases in drug discovery","volume":"13","author":"MacKenzie","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.bcp.2024.116667_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100924","article-title":"An overview of the non-canonical inflammasome","volume":"76","author":"Downs","year":"2020","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bcp.2024.116667_b1000","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.abb9818","article-title":"Succination inactivates gasdermin D and blocks pyroptosis","volume":"369","author":"Humphries","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116667_b1005","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b1010","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.1523\/JNEUROSCI.4587-15.2016","article-title":"Disulfiram and diphenhydramine hydrochloride upregulate miR-30a to suppress IL-17-associated autoimmune inflammation","volume":"36","author":"Zhao","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2024.116667_b1015","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1084\/jem.20190377","article-title":"Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis","volume":"216","author":"Li","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2024.116667_b1020","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41419-021-04349-5","article-title":"RelA\/MicroRNA-30a\/NLRP3 signal axis is involved in rheumatoid arthritis via regulating NLRP3 inflammasome in macrophages","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2024.116667_b1025","first-page":"447","article-title":"MiR-30a-5p and miR-153-3p regulate LPS-induced neuroinflammatory response and neuronal apoptosis by targeting NeuroD1","volume":"55","author":"Choi","year":"2022","journal-title":"Bmbrep"},{"key":"10.1016\/j.bcp.2024.116667_b1030","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4049\/jimmunol.2100977","article-title":"Identification of a small molecule with strong anti-inflammatory activity in experimental autoimmune encephalomyelitis and sepsis through blocking gasdermin D activation","volume":"209","author":"Cao","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b1035","first-page":"1","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","author":"Coll","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2024.116667_b1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102197","article-title":"Use of natural medicine and dietary supplements concomitant with conventional medicine among people with Multiple Sclerosis","volume":"44","author":"Bergien","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.bcp.2024.116667_b1045","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00415-006-0217-9","article-title":"Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis","volume":"253","author":"Apel","year":"2006","journal-title":"J. Neurol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:10:28Z","timestamp":1738818628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224006683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":209,"alternative-id":["S0006295224006683"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116667","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The NLRP3 inflammasome: A central player in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116667"}}